Akthelia Pharmaceuticals

Iceland
Reykjavík, Capital Region, Iceland, 101

Company profile

Akthelia Pharmaceuticals company profile

Akthelia is an emerging pharmaceutical company focused on the discovery and development of novel antimicrobial therapeutics, which enhance the body‘s innate microbial defences. The ever-increasing resistance to currently marketed antibiotics has led to a clear need for novel anti-infective agents that are active against drug resistant bacteria, opportunistic infections and acute infections of unknown causes. Akthelia has a diverse pipeline of products under development, targeting microbial infections. The current focus is on lung and gastrointestinal infections. In close collaboration with scientists at the Karolinska Institute in Stockholm and University of Iceland, evidence of new active ingredients and modes of action is being generated. The ensuing research is feeding the product pipeline and generating new product opportunities for further development.

Business identity

Contact email
[email protected]
Phone number
(354)510-1800
Operating status
Active
Company type
For Profit
Employee range
1-10 employees
Revenue range
$0+
Founded
2001-12-01

Headquarters

Postal code
101
Country code
IS
Continent
Europe

Capital profile

Funding and company signals

Funding stage
Seed
Funding rounds
5
Total equity funding
$317,435
Last funding
Grant / 2023-04-17
Last equity funding
Angel / $317,435
Investors
2
Lead investors
2
Founders
4
Articles
2

Founders and investors

Founders

Birgitta AgerberthEiríkur SteingrímssonGuðmundur Hrafn GuðmundssonRoger Strömberg

Lead investors

Horizon EuropeTechnology Development Fund

Investors

Horizon EuropeTechnology Development Fund